GlaxoSmithKline, Vir Biotechnology’s Covid drug reduces hospitalisation and death By Investing.com
By Samuel Indyk Investing.com – GlaxoSmithKline PLC (LON:GSK) and Vir Biotechnology Inc (NASDAQ:VIR) today announced their VIR-7831 antibody drug reduces hospitalisation or death of adults with Covid-19 by 85%. An Independent Data Monitoring Committee has now recommended the Phase 3 COMET-ICE trial evaluating the drug as a monotherapy for the early treatment of Covid-19 in adults at high risk of hospitalisation...
Continue reading